ID   HEM2_HUMAN              Reviewed;         330 AA.
AC   P13716; A8K375; B2R6F2; Q16870; Q16871; Q9BVQ9;
DT   01-JAN-1990, integrated into UniProtKB/Swiss-Prot.
DT   01-JAN-1990, sequence version 1.
DT   10-MAY-2017, entry version 192.
DE   RecName: Full=Delta-aminolevulinic acid dehydratase;
DE            Short=ALADH;
DE            EC=4.2.1.24;
DE   AltName: Full=Porphobilinogen synthase;
GN   Name=ALAD;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1).
RX   PubMed=3463993; DOI=10.1073/pnas.83.20.7703;
RA   Wetmur J.G., Bishop D.F., Cantelmo C., Desnick R.J.;
RT   "Human delta-aminolevulinate dehydratase: nucleotide sequence of a
RT   full-length cDNA clone.";
RL   Proc. Natl. Acad. Sci. U.S.A. 83:7703-7707(1986).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA].
RC   TISSUE=Liver;
RX   PubMed=1678509; DOI=10.1093/nar/19.15.4307-a;
RA   Wetmur J.G.;
RT   "RsaI polymorphism in the human delta-aminolevulinate dehydratase gene
RT   at 9q34.";
RL   Nucleic Acids Res. 19:4307-4307(1991).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), AND VARIANTS AHEPP TRP-240 AND
RP   THR-274.
RX   PubMed=1569184; DOI=10.1172/JCI115732;
RA   Ishida N., Fujita H., Fukuda Y., Noguchi T., Doss M., Kappas A.,
RA   Sassa S.;
RT   "Cloning and expression of the defective genes from a patient with
RT   delta-aminolevulinate dehydratase porphyria.";
RL   J. Clin. Invest. 89:1431-1437(1992).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORMS 1 AND 2).
RC   TISSUE=Brain, and Tongue;
RX   PubMed=14702039; DOI=10.1038/ng1285;
RA   Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R.,
RA   Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H.,
RA   Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S.,
RA   Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K.,
RA   Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A.,
RA   Sudo H., Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M.,
RA   Takahashi M., Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y.,
RA   Abe K., Kamihara K., Katsuta N., Sato K., Tanikawa M., Yamazaki M.,
RA   Ninomiya K., Ishibashi T., Yamashita H., Murakawa K., Fujimori K.,
RA   Tanai H., Kimata M., Watanabe M., Hiraoka S., Chiba Y., Ishida S.,
RA   Ono Y., Takiguchi S., Watanabe S., Yosida M., Hotuta T., Kusano J.,
RA   Kanehori K., Takahashi-Fujii A., Hara H., Tanase T.-O., Nomura Y.,
RA   Togiya S., Komai F., Hara R., Takeuchi K., Arita M., Imose N.,
RA   Musashino K., Yuuki H., Oshima A., Sasaki N., Aotsuka S.,
RA   Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S.,
RA   Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O.,
RA   Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H.,
RA   Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B.,
RA   Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y.,
RA   Fujimori Y., Komiyama M., Tashiro H., Tanigami A., Fujiwara T.,
RA   Ono T., Yamada K., Fujii Y., Ozaki K., Hirao M., Ohmori Y.,
RA   Kawabata A., Hikiji T., Kobatake N., Inagaki H., Ikema Y., Okamoto S.,
RA   Okitani R., Kawakami T., Noguchi S., Itoh T., Shigeta K., Senba T.,
RA   Matsumura K., Nakajima Y., Mizuno T., Morinaga M., Sasaki M.,
RA   Togashi T., Oyama M., Hata H., Watanabe M., Komatsu T.,
RA   Mizushima-Sugano J., Satoh T., Shirai Y., Takahashi Y., Nakagawa K.,
RA   Okumura K., Nagase T., Nomura N., Kikuchi H., Masuho Y., Yamashita R.,
RA   Nakai K., Yada T., Nakamura Y., Ohara O., Isogai T., Sugano S.;
RT   "Complete sequencing and characterization of 21,243 full-length human
RT   cDNAs.";
RL   Nat. Genet. 36:40-45(2004).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA], AND VARIANT ASN-59.
RG   NIEHS SNPs program;
RL   Submitted (JUN-2003) to the EMBL/GenBank/DDBJ databases.
RN   [6]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=15164053; DOI=10.1038/nature02465;
RA   Humphray S.J., Oliver K., Hunt A.R., Plumb R.W., Loveland J.E.,
RA   Howe K.L., Andrews T.D., Searle S., Hunt S.E., Scott C.E., Jones M.C.,
RA   Ainscough R., Almeida J.P., Ambrose K.D., Ashwell R.I.S.,
RA   Babbage A.K., Babbage S., Bagguley C.L., Bailey J., Banerjee R.,
RA   Barker D.J., Barlow K.F., Bates K., Beasley H., Beasley O., Bird C.P.,
RA   Bray-Allen S., Brown A.J., Brown J.Y., Burford D., Burrill W.,
RA   Burton J., Carder C., Carter N.P., Chapman J.C., Chen Y., Clarke G.,
RA   Clark S.Y., Clee C.M., Clegg S., Collier R.E., Corby N., Crosier M.,
RA   Cummings A.T., Davies J., Dhami P., Dunn M., Dutta I., Dyer L.W.,
RA   Earthrowl M.E., Faulkner L., Fleming C.J., Frankish A.,
RA   Frankland J.A., French L., Fricker D.G., Garner P., Garnett J.,
RA   Ghori J., Gilbert J.G.R., Glison C., Grafham D.V., Gribble S.,
RA   Griffiths C., Griffiths-Jones S., Grocock R., Guy J., Hall R.E.,
RA   Hammond S., Harley J.L., Harrison E.S.I., Hart E.A., Heath P.D.,
RA   Henderson C.D., Hopkins B.L., Howard P.J., Howden P.J., Huckle E.,
RA   Johnson C., Johnson D., Joy A.A., Kay M., Keenan S., Kershaw J.K.,
RA   Kimberley A.M., King A., Knights A., Laird G.K., Langford C.,
RA   Lawlor S., Leongamornlert D.A., Leversha M., Lloyd C., Lloyd D.M.,
RA   Lovell J., Martin S., Mashreghi-Mohammadi M., Matthews L., McLaren S.,
RA   McLay K.E., McMurray A., Milne S., Nickerson T., Nisbett J.,
RA   Nordsiek G., Pearce A.V., Peck A.I., Porter K.M., Pandian R.,
RA   Pelan S., Phillimore B., Povey S., Ramsey Y., Rand V., Scharfe M.,
RA   Sehra H.K., Shownkeen R., Sims S.K., Skuce C.D., Smith M.,
RA   Steward C.A., Swarbreck D., Sycamore N., Tester J., Thorpe A.,
RA   Tracey A., Tromans A., Thomas D.W., Wall M., Wallis J.M., West A.P.,
RA   Whitehead S.L., Willey D.L., Williams S.A., Wilming L., Wray P.W.,
RA   Young L., Ashurst J.L., Coulson A., Blocker H., Durbin R.M.,
RA   Sulston J.E., Hubbard T., Jackson M.J., Bentley D.R., Beck S.,
RA   Rogers J., Dunham I.;
RT   "DNA sequence and analysis of human chromosome 9.";
RL   Nature 429:369-374(2004).
RN   [7]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1).
RC   TISSUE=Placenta;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [8]
RP   PROTEIN SEQUENCE OF 1-17.
RC   TISSUE=Platelet;
RX   PubMed=12665801; DOI=10.1038/nbt810;
RA   Gevaert K., Goethals M., Martens L., Van Damme J., Staes A.,
RA   Thomas G.R., Vandekerckhove J.;
RT   "Exploring proteomes and analyzing protein processing by mass
RT   spectrometric identification of sorted N-terminal peptides.";
RL   Nat. Biotechnol. 21:566-569(2003).
RN   [9]
RP   ACTIVE SITE.
RX   PubMed=3092810; DOI=10.1042/bj2360447;
RA   Gibbs P.N.B., Jordan P.M.;
RT   "Identification of lysine at the active site of human 5-
RT   aminolevulinate dehydratase.";
RL   Biochem. J. 236:447-451(1986).
RN   [10]
RP   POLYMORPHISM, AND VARIANT ASN-59.
RX   PubMed=1769358; DOI=10.1016/S0013-9351(05)80001-5;
RA   Wetmur J.G., Lehnert G., Desnick R.J.;
RT   "The delta-aminolevulinate dehydratase polymorphism: higher blood lead
RT   levels in lead workers and environmentally exposed children with the
RT   1-2 and 2-2 isozymes.";
RL   Environ. Res. 56:109-119(1991).
RN   [11]
RP   ENZYME REGULATION, FUNCTION, CATALYTIC ACTIVITY, BIOPHYSICOCHEMICAL
RP   PROPERTIES, COFACTOR, IDENTIFICATION BY MASS SPECTROMETRY, MUTAGENESIS
RP   OF CYS-122; CYS-124; HIS-131; CYS-132 AND CYS-223, AND
RP   CHARACTERIZATION OF VARIANT ASN-59.
RX   PubMed=11032836; DOI=10.1074/jbc.M007663200;
RA   Jaffe E.K., Martins J., Li J., Kervinen J., Dunbrack R.L. Jr.;
RT   "The molecular mechanism of lead inhibition of human porphobilinogen
RT   synthase.";
RL   J. Biol. Chem. 276:1531-1537(2001).
RN   [12]
RP   POLYMORPHISM.
RX   PubMed=17966070; DOI=10.1080/15287390701550946;
RA   Zhao Y., Wang L., Shen H.B., Wang Z.X., Wei Q.Y., Chen F.;
RT   "Association between delta-aminolevulinic acid dehydratase (ALAD)
RT   polymorphism and blood lead levels: a meta-regression analysis.";
RL   J. Toxicol. Environ. Health Part A 70:1986-1994(2007).
RN   [13]
RP   FUNCTION, CATALYTIC ACTIVITY, SUBUNIT, AND ENZYME REGULATION.
RX   PubMed=19812033; DOI=10.1074/jbc.M109.026294;
RA   Lawrence S.H., Ramirez U.D., Selwood T., Stith L., Jaffe E.K.;
RT   "Allosteric inhibition of human porphobilinogen synthase.";
RL   J. Biol. Chem. 284:35807-35817(2009).
RN   [14]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21269460; DOI=10.1186/1752-0509-5-17;
RA   Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P.,
RA   Buerckstuemmer T., Bennett K.L., Superti-Furga G., Colinge J.;
RT   "Initial characterization of the human central proteome.";
RL   BMC Syst. Biol. 5:17-17(2011).
RN   [15]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Liver;
RX   PubMed=24275569; DOI=10.1016/j.jprot.2013.11.014;
RA   Bian Y., Song C., Cheng K., Dong M., Wang F., Huang J., Sun D.,
RA   Wang L., Ye M., Zou H.;
RT   "An enzyme assisted RP-RPLC approach for in-depth analysis of human
RT   liver phosphoproteome.";
RL   J. Proteomics 96:253-262(2014).
RN   [16]
RP   X-RAY CRYSTALLOGRAPHY (2.83 ANGSTROMS) IN COMPLEX WITH PORPHOBILINOGEN
RP   AND ZINC IONS.
RA   Mills-Davies N.L., Thompson D., Cooper J.B., Shoolingin-Jordan P.M.;
RT   "The crystal structure of human Ala-dehydratase.";
RL   Submitted (OCT-1998) to the PDB data bank.
RN   [17]
RP   X-RAY CRYSTALLOGRAPHY (2.2 ANGSTROMS) OF MUTANT LEU-12 IN COMPLEX WITH
RP   SUBSTRATE ANALOG, SUBUNIT, IDENTIFICATION BY MASS SPECTROMETRY,
RP   CATALYTIC ACTIVITY, AND ENZYME REGULATION.
RX   PubMed=12897770; DOI=10.1038/nsb963;
RA   Breinig S., Kervinen J., Stith L., Wasson A.S., Fairman R.,
RA   Wlodawer A., Zdanov A., Jaffe E.K.;
RT   "Control of tetrapyrrole biosynthesis by alternate quaternary forms of
RT   porphobilinogen synthase.";
RL   Nat. Struct. Biol. 10:757-763(2003).
RN   [18]
RP   POLYMORPHISM, AND VARIANT ASN-59.
RX   PubMed=1716854;
RA   Wetmur J.G., Kaya A.H., Plewinska M., Desnick R.J.;
RT   "Molecular characterization of the human delta-aminolevulinate
RT   dehydratase 2 (ALAD2) allele: implications for molecular screening of
RT   individuals for genetic susceptibility to lead poisoning.";
RL   Am. J. Hum. Genet. 49:757-763(1991).
RN   [19]
RP   VARIANTS AHEPP ARG-133 AND MET-275.
RX   PubMed=2063868;
RA   Plewinska M., Thunell S., Holmberg L., Wetmur J.G., Desnick R.J.;
RT   "Delta-aminolevulinate dehydratase deficient porphyria: identification
RT   of the molecular lesions in a severely affected homozygote.";
RL   Am. J. Hum. Genet. 49:167-174(1991).
RN   [20]
RP   VARIANTS AHEPP TRP-240 AND THR-274, AND CHARACTERIZATION OF VARIANTS
RP   AHEPP TRP-240 AND THR-274.
RX   PubMed=1309003;
RA   Sassa S., Ishida N., Fujita H., Fukuda Y., Noguchi T., Doss M.,
RA   Kappas A.;
RT   "Cloning and expression of the defective genes in delta-
RT   aminolevulinate dehydratase porphyria: compound heterozygosity in this
RT   hereditary liver disease.";
RL   Trans. Assoc. Am. Physicians 105:250-259(1992).
RN   [21]
RP   VARIANT LEU-12, AND CHARACTERIZATION OF VARIANT LEU-12.
RX   PubMed=10519994; DOI=10.1046/j.1365-2141.1999.01647.x;
RA   Akagi R., Yasui Y., Harper P., Sassa S.;
RT   "A novel mutation of delta-aminolaevulinate dehydratase in a healthy
RT   child with 12% erythrocyte enzyme activity.";
RL   Br. J. Haematol. 106:931-937(1999).
RN   [22]
RP   VARIANT AHEPP MET-153, AND CHARACTERIZATION OF VARIANT AHEPP MET-153.
RX   PubMed=10706561; DOI=10.1002/hep.510310321;
RA   Akagi R., Shimizu R., Furuyama K., Doss M.O., Sassa S.;
RT   "Novel molecular defects of the delta-aminolevulinate dehydratase gene
RT   in a patient with inherited acute hepatic porphyria.";
RL   Hepatology 31:704-708(2000).
RN   [23]
RP   VARIANT LEU-12.
RX   PubMed=16398658; DOI=10.1111/j.1365-2141.2005.05852.x;
RA   Akagi R., Inoue R., Muranaka S., Tahara T., Taketani S.,
RA   Anderson K.E., Phillips J.D., Sassa S.;
RT   "Dual gene defects involving delta-aminolaevulinate dehydratase and
RT   coproporphyrinogen oxidase in a porphyria patient.";
RL   Br. J. Haematol. 132:237-243(2006).
RN   [24]
RP   CHARACTERIZATION OF VARIANTS AHEPP ARG-133; MET-153; TRP-240; THR-274
RP   AND MET-275, AND CHARACTERIZATION OF VARIANTS LEU-12 AND ASN-59.
RX   PubMed=17236137; DOI=10.1086/511444;
RA   Jaffe E.K., Stith L.;
RT   "ALAD porphyria is a conformational disease.";
RL   Am. J. Hum. Genet. 80:329-337(2007).
CC   -!- FUNCTION: Catalyzes an early step in the biosynthesis of
CC       tetrapyrroles. Binds two molecules of 5-aminolevulinate per
CC       subunit, each at a distinct site, and catalyzes their condensation
CC       to form porphobilinogen. {ECO:0000269|PubMed:11032836,
CC       ECO:0000269|PubMed:19812033}.
CC   -!- CATALYTIC ACTIVITY: 2 5-aminolevulinate = porphobilinogen + 2
CC       H(2)O. {ECO:0000269|PubMed:11032836, ECO:0000269|PubMed:12897770,
CC       ECO:0000269|PubMed:19812033}.
CC   -!- COFACTOR:
CC       Name=Zn(2+); Xref=ChEBI:CHEBI:29105;
CC         Evidence={ECO:0000269|PubMed:11032836};
CC       Note=Binds 8 zinc ions per octamer. Requires four zinc ions per
CC       octamer for full catalytic activity. Can bind up to 2 zinc ions
CC       per subunit. {ECO:0000269|PubMed:11032836};
CC   -!- ENZYME REGULATION: Can alternate between a fully active
CC       homooctamer and a low-activity homohexamer. A bound magnesium ion
CC       may promote the assembly of the fully active homooctamer. The
CC       magnesium-binding site is absent in the low-activity homohexamer.
CC       Inhibited by compounds that favor the hexameric state. Inhibited
CC       by divalent lead ions. The lead ions partially displace the zinc
CC       cofactor. {ECO:0000269|PubMed:11032836,
CC       ECO:0000269|PubMed:12897770, ECO:0000269|PubMed:19812033}.
CC   -!- BIOPHYSICOCHEMICAL PROPERTIES:
CC       Kinetic parameters:
CC         KM=0.09 mM for 5-aminolevulinate at pH 7
CC         {ECO:0000269|PubMed:11032836};
CC         Vmax=43 umol/h/mg enzyme at pH 7 {ECO:0000269|PubMed:11032836};
CC       pH dependence:
CC         Optimum pH is 6.8-7.3. {ECO:0000269|PubMed:11032836};
CC   -!- PATHWAY: Porphyrin-containing compound metabolism; protoporphyrin-
CC       IX biosynthesis; coproporphyrinogen-III from 5-aminolevulinate:
CC       step 1/4.
CC   -!- SUBUNIT: Homooctamer; active form. Homohexamer; low activity form.
CC       {ECO:0000269|PubMed:12897770, ECO:0000269|PubMed:19812033,
CC       ECO:0000269|Ref.16}.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=2;
CC       Name=1;
CC         IsoId=P13716-1; Sequence=Displayed;
CC       Name=2;
CC         IsoId=P13716-2; Sequence=VSP_037866;
CC   -!- POLYMORPHISM: Genetic variation in ALAD influences susceptibility
CC       to lead poisoning in individuals exposed to high amount of
CC       environmental lead. There are two common alleles: allele ALAD*1
CC       and allele ALAD*2 resulting in 3 isozymes: ALAD 1-1, ALAD 1-2, and
CC       ALAD 2-2. Individuals with ALAD 1-2 or ALAD 2-2 isozymes have
CC       levels of blood lead higher than those in individuals with ALAD 1-
CC       1 isozyme. The sequence shown corresponds to allele ALAD*1.
CC       {ECO:0000269|PubMed:1716854, ECO:0000269|PubMed:1769358,
CC       ECO:0000305|PubMed:17966070}.
CC   -!- DISEASE: Acute hepatic porphyria (AHEPP) [MIM:612740]: A form of
CC       porphyria. Porphyrias are inherited defects in the biosynthesis of
CC       heme, resulting in the accumulation and increased excretion of
CC       porphyrins or porphyrin precursors. They are classified as
CC       erythropoietic or hepatic, depending on whether the enzyme
CC       deficiency occurs in red blood cells or in the liver. AHP is
CC       characterized by attacks of gastrointestinal disturbances,
CC       abdominal colic, paralyses and peripheral neuropathy. Most attacks
CC       are precipitated by drugs, alcohol, caloric deprivation,
CC       infections, or endocrine factors. {ECO:0000269|PubMed:10706561,
CC       ECO:0000269|PubMed:1309003, ECO:0000269|PubMed:1569184,
CC       ECO:0000269|PubMed:17236137, ECO:0000269|PubMed:2063868}. Note=The
CC       disease is caused by mutations affecting the gene represented in
CC       this entry.
CC   -!- SIMILARITY: Belongs to the ALAD family. {ECO:0000305}.
CC   -!- SEQUENCE CAUTION:
CC       Sequence=AAH00977.3; Type=Erroneous initiation; Evidence={ECO:0000305};
CC   -!- WEB RESOURCE: Name=NIEHS-SNPs;
CC       URL="http://egp.gs.washington.edu/data/alad/";
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; M13928; AAA51687.1; -; mRNA.
DR   EMBL; X64467; CAA45796.1; -; Genomic_DNA.
DR   EMBL; S99468; AAC60581.1; -; mRNA.
DR   EMBL; S99471; AAC60582.1; -; mRNA.
DR   EMBL; AK290490; BAF83179.1; -; mRNA.
DR   EMBL; AK312552; BAG35449.1; -; mRNA.
DR   EMBL; AY319481; AAP72012.1; -; Genomic_DNA.
DR   EMBL; AL137066; CAH70099.3; -; Genomic_DNA.
DR   EMBL; BC000977; AAH00977.3; ALT_INIT; mRNA.
DR   CCDS; CCDS6794.2; -. [P13716-1]
DR   PIR; A26478; A26478.
DR   RefSeq; NP_000022.3; NM_000031.5. [P13716-1]
DR   RefSeq; NP_001003945.1; NM_001003945.2. [P13716-2]
DR   RefSeq; XP_011516666.1; XM_011518364.2.
DR   UniGene; Hs.1227; -.
DR   PDB; 1E51; X-ray; 2.83 A; A/B=1-330.
DR   PDB; 1PV8; X-ray; 2.20 A; A/B=1-330.
DR   PDB; 5HMS; X-ray; 2.80 A; A/B=1-330.
DR   PDB; 5HNR; X-ray; 2.83 A; A/B=1-330.
DR   PDBsum; 1E51; -.
DR   PDBsum; 1PV8; -.
DR   PDBsum; 5HMS; -.
DR   PDBsum; 5HNR; -.
DR   ProteinModelPortal; P13716; -.
DR   SMR; P13716; -.
DR   BioGrid; 106712; 22.
DR   IntAct; P13716; 1.
DR   STRING; 9606.ENSP00000386284; -.
DR   BindingDB; P13716; -.
DR   ChEMBL; CHEMBL3126; -.
DR   DrugBank; DB02878; 3-(2-Aminoethyl)-4-(Aminomethyl)Heptanedioic Acid.
DR   DrugBank; DB02260; 4-Oxosebacic Acid.
DR   DrugBank; DB04781; 5-hydroxyvaleric acid.
DR   DrugBank; DB00855; Aminolevulinic acid.
DR   DrugBank; DB02068; Delta-Amino Valeric Acid.
DR   DrugBank; DB02239; Laevulinic Acid.
DR   DrugBank; DB02272; Porphobilinogen.
DR   iPTMnet; P13716; -.
DR   PhosphoSitePlus; P13716; -.
DR   SwissPalm; P13716; -.
DR   BioMuta; ALAD; -.
DR   DMDM; 122833; -.
DR   OGP; P13716; -.
DR   REPRODUCTION-2DPAGE; P13716; -.
DR   SWISS-2DPAGE; P13716; -.
DR   EPD; P13716; -.
DR   MaxQB; P13716; -.
DR   PaxDb; P13716; -.
DR   PeptideAtlas; P13716; -.
DR   PRIDE; P13716; -.
DR   Ensembl; ENST00000409155; ENSP00000386284; ENSG00000148218. [P13716-1]
DR   GeneID; 210; -.
DR   KEGG; hsa:210; -.
DR   UCSC; uc011lxf.3; human. [P13716-1]
DR   CTD; 210; -.
DR   DisGeNET; 210; -.
DR   GeneCards; ALAD; -.
DR   HGNC; HGNC:395; ALAD.
DR   HPA; HPA021023; -.
DR   HPA; HPA022124; -.
DR   MalaCards; ALAD; -.
DR   MIM; 125270; gene.
DR   MIM; 612740; phenotype.
DR   neXtProt; NX_P13716; -.
DR   OpenTargets; ENSG00000148218; -.
DR   Orphanet; 100924; Porphyria due to ALA dehydratase deficiency.
DR   PharmGKB; PA24687; -.
DR   eggNOG; KOG2794; Eukaryota.
DR   eggNOG; COG0113; LUCA.
DR   GeneTree; ENSGT00390000006998; -.
DR   HOGENOM; HOG000020323; -.
DR   HOVERGEN; HBG001222; -.
DR   InParanoid; P13716; -.
DR   KO; K01698; -.
DR   OMA; MHHATLR; -.
DR   OrthoDB; EOG091G0FMX; -.
DR   PhylomeDB; P13716; -.
DR   TreeFam; TF300665; -.
DR   BioCyc; MetaCyc:HS07501-MONOMER; -.
DR   BRENDA; 4.2.1.24; 2681.
DR   Reactome; R-HSA-189451; Heme biosynthesis.
DR   Reactome; R-HSA-6798695; Neutrophil degranulation.
DR   UniPathway; UPA00251; UER00318.
DR   ChiTaRS; ALAD; human.
DR   EvolutionaryTrace; P13716; -.
DR   GeneWiki; ALAD; -.
DR   GenomeRNAi; 210; -.
DR   PRO; PR:P13716; -.
DR   Proteomes; UP000005640; Chromosome 9.
DR   Bgee; ENSG00000148218; -.
DR   CleanEx; HS_ALAD; -.
DR   ExpressionAtlas; P13716; baseline and differential.
DR   Genevisible; P13716; HS.
DR   GO; GO:0005829; C:cytosol; IBA:GO_Central.
DR   GO; GO:0070062; C:extracellular exosome; IDA:UniProtKB.
DR   GO; GO:0005576; C:extracellular region; TAS:Reactome.
DR   GO; GO:0005615; C:extracellular space; IEA:Ensembl.
DR   GO; GO:1904813; C:ficolin-1-rich granule lumen; TAS:Reactome.
DR   GO; GO:0005634; C:nucleus; IDA:UniProtKB.
DR   GO; GO:0034774; C:secretory granule lumen; TAS:Reactome.
DR   GO; GO:0003824; F:catalytic activity; TAS:ProtInc.
DR   GO; GO:0042802; F:identical protein binding; IPI:UniProtKB.
DR   GO; GO:0004655; F:porphobilinogen synthase activity; IDA:UniProtKB.
DR   GO; GO:0008270; F:zinc ion binding; IDA:UniProtKB.
DR   GO; GO:0071353; P:cellular response to interleukin-4; IEA:Ensembl.
DR   GO; GO:0071284; P:cellular response to lead ion; IEA:Ensembl.
DR   GO; GO:0006783; P:heme biosynthetic process; IDA:UniProtKB.
DR   GO; GO:1901799; P:negative regulation of proteasomal protein catabolic process; IDA:CAFA.
DR   GO; GO:0043312; P:neutrophil degranulation; TAS:Reactome.
DR   GO; GO:0051260; P:protein homooligomerization; IPI:UniProtKB.
DR   GO; GO:0006782; P:protoporphyrinogen IX biosynthetic process; IEA:UniProtKB-UniPathway.
DR   GO; GO:0014823; P:response to activity; IEA:Ensembl.
DR   GO; GO:0010044; P:response to aluminum ion; IEA:Ensembl.
DR   GO; GO:0043200; P:response to amino acid; IEA:Ensembl.
DR   GO; GO:0046685; P:response to arsenic-containing substance; IEA:Ensembl.
DR   GO; GO:0046686; P:response to cadmium ion; IEA:Ensembl.
DR   GO; GO:0032025; P:response to cobalt ion; IEA:Ensembl.
DR   GO; GO:0042493; P:response to drug; IEA:Ensembl.
DR   GO; GO:0045471; P:response to ethanol; IEA:Ensembl.
DR   GO; GO:0070542; P:response to fatty acid; IEA:Ensembl.
DR   GO; GO:0051384; P:response to glucocorticoid; IEA:Ensembl.
DR   GO; GO:0009635; P:response to herbicide; IEA:Ensembl.
DR   GO; GO:0001666; P:response to hypoxia; IEA:Ensembl.
DR   GO; GO:0010212; P:response to ionizing radiation; IEA:Ensembl.
DR   GO; GO:0010039; P:response to iron ion; IEA:Ensembl.
DR   GO; GO:0032496; P:response to lipopolysaccharide; IEA:Ensembl.
DR   GO; GO:0046689; P:response to mercury ion; IEA:Ensembl.
DR   GO; GO:0051597; P:response to methylmercury; IEA:Ensembl.
DR   GO; GO:0006979; P:response to oxidative stress; IEA:Ensembl.
DR   GO; GO:0070541; P:response to platinum ion; IEA:Ensembl.
DR   GO; GO:0010269; P:response to selenium ion; IEA:Ensembl.
DR   GO; GO:0010266; P:response to vitamin B1; IEA:Ensembl.
DR   GO; GO:0033197; P:response to vitamin E; IEA:Ensembl.
DR   GO; GO:0010043; P:response to zinc ion; IEA:Ensembl.
DR   Gene3D; 3.20.20.70; -; 1.
DR   InterPro; IPR001731; ALAD.
DR   InterPro; IPR030656; ALAD_AS.
DR   InterPro; IPR013785; Aldolase_TIM.
DR   PANTHER; PTHR11458; PTHR11458; 1.
DR   Pfam; PF00490; ALAD; 1.
DR   PIRSF; PIRSF001415; Porphbilin_synth; 1.
DR   PRINTS; PR00144; DALDHYDRTASE.
DR   SMART; SM01004; ALAD; 1.
DR   PROSITE; PS00169; D_ALA_DEHYDRATASE; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Allosteric enzyme; Alternative splicing;
KW   Complete proteome; Direct protein sequencing; Disease mutation;
KW   Heme biosynthesis; Lyase; Metal-binding; Phosphoprotein; Polymorphism;
KW   Porphyrin biosynthesis; Reference proteome; Zinc.
FT   CHAIN         1    330       Delta-aminolevulinic acid dehydratase.
FT                                /FTId=PRO_0000140526.
FT   ACT_SITE    199    199       Schiff-base intermediate with substrate.
FT                                {ECO:0000269|PubMed:3092810}.
FT   ACT_SITE    252    252       Schiff-base intermediate with substrate.
FT                                {ECO:0000269|PubMed:3092810}.
FT   METAL       122    122       Zinc 1; catalytic.
FT   METAL       124    124       Zinc 1; catalytic.
FT   METAL       131    131       Zinc 2.
FT   METAL       132    132       Zinc 1; catalytic.
FT   METAL       223    223       Zinc 2.
FT   BINDING     209    209       Substrate 1.
FT   BINDING     221    221       Substrate 1.
FT   BINDING     279    279       Substrate 2.
FT   BINDING     318    318       Substrate 2.
FT   MOD_RES     199    199       N6-succinyllysine.
FT                                {ECO:0000250|UniProtKB:P10518}.
FT   MOD_RES     215    215       Phosphoserine.
FT                                {ECO:0000250|UniProtKB:P10518}.
FT   MOD_RES     252    252       N6-succinyllysine.
FT                                {ECO:0000250|UniProtKB:P10518}.
FT   VAR_SEQ       1     38       MQPQSVLHSGYFHPLLRAWQTATTTLNASNLIYPIFVT ->
FT                                MPPTSSTPSLSRPGLGQAGKPDTGSHPPPTISTSIFLSCFP
FT                                TIPLSRPRTTGPSHSYQSISHPRSCR (in isoform
FT                                2). {ECO:0000303|PubMed:14702039}.
FT                                /FTId=VSP_037866.
FT   VARIANT      12     12       F -> L (in an asymptomatic patient with
FT                                ALAD deficiency; also found in a
FT                                hereditary coproporphyria patient
FT                                carrying the R-279 mutation in CPOX;
FT                                hexamer with almost no residual activity;
FT                                dbSNP:rs121912984).
FT                                {ECO:0000269|PubMed:10519994,
FT                                ECO:0000269|PubMed:16398658,
FT                                ECO:0000269|PubMed:17236137}.
FT                                /FTId=VAR_020973.
FT   VARIANT      59     59       K -> N (common polymorphism; allele
FT                                ALAD*2; ALAD*2 heterozygous or homozygous
FT                                carriers have significantly higher blood
FT                                lead levels than ALAD*1 homozygotes when
FT                                exposed to environmental lead; fully
FT                                active octamer; dbSNP:rs1800435).
FT                                {ECO:0000269|PubMed:11032836,
FT                                ECO:0000269|PubMed:1716854,
FT                                ECO:0000269|PubMed:17236137,
FT                                ECO:0000269|PubMed:1769358,
FT                                ECO:0000269|Ref.5}.
FT                                /FTId=VAR_003633.
FT   VARIANT     133    133       G -> R (in AHEPP; mixture of about 50%
FT                                hexamer and 50% octamer; about 10%
FT                                residual activity; dbSNP:rs121912980).
FT                                {ECO:0000269|PubMed:17236137,
FT                                ECO:0000269|PubMed:2063868}.
FT                                /FTId=VAR_003634.
FT   VARIANT     153    153       V -> M (in AHEPP; about 95% octamer;
FT                                about 40% residual activity).
FT                                {ECO:0000269|PubMed:10706561,
FT                                ECO:0000269|PubMed:17236137}.
FT                                /FTId=VAR_020974.
FT   VARIANT     240    240       R -> W (in AHEPP; mixture of about 80%
FT                                hexamer and 20% octamer; about 4%
FT                                residual activity; dbSNP:rs121912982).
FT                                {ECO:0000269|PubMed:1309003,
FT                                ECO:0000269|PubMed:1569184,
FT                                ECO:0000269|PubMed:17236137}.
FT                                /FTId=VAR_003635.
FT   VARIANT     274    274       A -> T (in AHEPP; mixture of about 14%
FT                                hexamer and 86% octamer; about 20% enzyme
FT                                residual activity; dbSNP:rs121912983).
FT                                {ECO:0000269|PubMed:1309003,
FT                                ECO:0000269|PubMed:1569184,
FT                                ECO:0000269|PubMed:17236137}.
FT                                /FTId=VAR_003636.
FT   VARIANT     275    275       V -> M (in AHEPP; mainly octamer; reduced
FT                                activity; dbSNP:rs121912981).
FT                                {ECO:0000269|PubMed:17236137,
FT                                ECO:0000269|PubMed:2063868}.
FT                                /FTId=VAR_003637.
FT   MUTAGEN     122    122       C->A: Reduces enzyme activity about
FT                                1000000-fold; when associated with A-124
FT                                and A-132. {ECO:0000269|PubMed:11032836}.
FT   MUTAGEN     124    124       C->A: Reduces enzyme activity about
FT                                1000000-fold; when associated with A-122
FT                                and A-132. {ECO:0000269|PubMed:11032836}.
FT   MUTAGEN     131    131       H->A: No effect on catalytic activity;
FT                                when associated with A-223.
FT                                {ECO:0000269|PubMed:11032836}.
FT   MUTAGEN     132    132       C->A: Reduces enzyme activity about
FT                                1000000-fold; when associated with A-122
FT                                and A-124. {ECO:0000269|PubMed:11032836}.
FT   MUTAGEN     223    223       C->A: No effect on catalytic activity;
FT                                when associated with A-131.
FT                                {ECO:0000269|PubMed:11032836}.
FT   HELIX         8     10       {ECO:0000244|PDB:5HMS}.
FT   STRAND       11     13       {ECO:0000244|PDB:5HMS}.
FT   HELIX        14     20       {ECO:0000244|PDB:1PV8}.
FT   TURN         21     24       {ECO:0000244|PDB:1PV8}.
FT   HELIX        28     30       {ECO:0000244|PDB:1PV8}.
FT   STRAND       31     37       {ECO:0000244|PDB:1PV8}.
FT   STRAND       44     46       {ECO:0000244|PDB:1PV8}.
FT   STRAND       48     50       {ECO:0000244|PDB:1PV8}.
FT   STRAND       54     56       {ECO:0000244|PDB:1PV8}.
FT   HELIX        58     71       {ECO:0000244|PDB:1PV8}.
FT   STRAND       75     80       {ECO:0000244|PDB:1PV8}.
FT   STRAND       83     85       {ECO:0000244|PDB:5HMS}.
FT   STRAND       88     90       {ECO:0000244|PDB:5HMS}.
FT   HELIX        92     94       {ECO:0000244|PDB:5HMS}.
FT   HELIX       100    111       {ECO:0000244|PDB:1PV8}.
FT   STRAND      115    121       {ECO:0000244|PDB:1PV8}.
FT   HELIX       124    126       {ECO:0000244|PDB:5HMS}.
FT   STRAND      127    129       {ECO:0000244|PDB:5HMS}.
FT   STRAND      131    133       {ECO:0000244|PDB:5HNR}.
FT   STRAND      137    139       {ECO:0000244|PDB:5HMS}.
FT   HELIX       141    160       {ECO:0000244|PDB:1PV8}.
FT   STRAND      163    167       {ECO:0000244|PDB:1PV8}.
FT   HELIX       174    184       {ECO:0000244|PDB:1PV8}.
FT   TURN        188    190       {ECO:0000244|PDB:1PV8}.
FT   STRAND      192    194       {ECO:0000244|PDB:1PV8}.
FT   STRAND      198    200       {ECO:0000244|PDB:5HMS}.
FT   HELIX       203    205       {ECO:0000244|PDB:1PV8}.
FT   HELIX       206    210       {ECO:0000244|PDB:1PV8}.
FT   STRAND      217    219       {ECO:0000244|PDB:5HMS}.
FT   TURN        222    224       {ECO:0000244|PDB:5HMS}.
FT   HELIX       231    243       {ECO:0000244|PDB:1PV8}.
FT   STRAND      247    253       {ECO:0000244|PDB:1PV8}.
FT   HELIX       255    257       {ECO:0000244|PDB:1PV8}.
FT   HELIX       258    267       {ECO:0000244|PDB:1PV8}.
FT   STRAND      273    277       {ECO:0000244|PDB:1PV8}.
FT   HELIX       279    290       {ECO:0000244|PDB:1PV8}.
FT   HELIX       296    310       {ECO:0000244|PDB:1PV8}.
FT   STRAND      313    317       {ECO:0000244|PDB:1PV8}.
FT   HELIX       320    326       {ECO:0000244|PDB:1PV8}.
FT   TURN        327    329       {ECO:0000244|PDB:1PV8}.
SQ   SEQUENCE   330 AA;  36295 MW;  E005F3055F6D9403 CRC64;
     MQPQSVLHSG YFHPLLRAWQ TATTTLNASN LIYPIFVTDV PDDIQPITSL PGVARYGVKR
     LEEMLRPLVE EGLRCVLIFG VPSRVPKDER GSAADSEESP AIEAIHLLRK TFPNLLVACD
     VCLCPYTSHG HCGLLSENGA FRAEESRQRL AEVALAYAKA GCQVVAPSDM MDGRVEAIKE
     ALMAHGLGNR VSVMSYSAKF ASCFYGPFRD AAKSSPAFGD RRCYQLPPGA RGLALRAVDR
     DVREGADMLM VKPGMPYLDI VREVKDKHPD LPLAVYHVSG EFAMLWHGAQ AGAFDLKAAV
     LEAMTAFRRA GADIIITYYT PQLLQWLKEE
//
